Recently we shared some updates on REGENXBIO’s investigational gene therapy programs for the treatment of CLN2 Batten disease.

We are pleased to share this letter with the CLN2 Batten disease community, where REGENXBIO reports some initial interim data from a first-in-human, single-patient, investigator-initiated trial of “RGX-181” delivered directly into the brain.

You can read the letter here:

http://www.bdfa-uk.org.uk/wp-content/uploads/2023/10/CLN2-community-letter_RGX-181-FINAL_Oct-5-2023.pdf